Drugs / GenSci139
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07230977 | Nov 2025 → Jul 2028 expected | cancer | Changchun GeneScience Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2026-04-27 | Changchun GeneScience Pharmaceutical Co., Ltd. | Results GenSci Presents Multiple Innovative Oncology Pipelines at AACR 2026 genscigroup.com ↗
In multiple mouse CDX models, GenSci139 has showed significantly potent in vivo antitumor efficacy and possesses broad therapeutic potential across various solid tumors, including urothelial carcinoma, lung cancer, gastric cancer, colorectal cancer, ovarian cancer and breast cancer. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-04-27 | Changchun GeneScience Pharmaceutical Co., Ltd. | GenSci Presents Multiple Innovative Oncology Pipelines at AACR 2026 genscigroup.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GenSci139 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07230977 ↗ |
| Modality | Other / unclassified | “bispecific antibody drug conjugate” NCT07230977 ↗ |
| Target | EGFR | “targeting EGFR and HER2” NCT07230977 ↗ |
| Target | HER2 | “targeting EGFR and HER2” NCT07230977 ↗ |